Loading
Nanoparticle-based Drug Delivery / Cancer, Hypoxia, and Metabolism / Nanoplatforms for Cancer Theranostics · Journal article
Journal of Nanobiotechnology · September 7, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical proof-of-concept study of a Cu-deficient Prussian blue nanoparticle conjugate designed to exploit tumor microenvironment conditions (phosphate, GSH) for enhanced catalytic and sonodynamic activity. In vitro data and a single 4T1 breast tumor model showed tumor growth suppression and favorable biosafety, but the study lacks quantified efficacy metrics, controlled comparators, and information necessary to assess reproducibility or generalizability.
Preclinical in vitro and in vivo study. 4T1 mouse breast cancer cells (in vitro) and 4T1 breast tumor-bearing mice (in vivo). No inclusion/exclusion criteria, animal sex, age, or sample justification reported.. Intervention: CuPBA-D/HMME/HA nanoparticle with ultrasound irradiation.. Compared with: Not explicitly stated; no control or comparator treatment group described.. Not stated..
Cu deficiency enhanced H₂O₂ adsorption and activation, favoring O₂•− generation under mildly acidic conditions and O₂ evolution near neutrality. Phosphate-containing media increased surface fractions of higher-valence Cu/Fe species and accelerated GSH consumption by CuPBA-D. CuPBA-D underwent GSH-concentration-dependent framework disassembly in the presence of phosphate and GSH, indicating coupled redox and structural evolution.
No comparison to standard-of-care or positive-control treatments; 'favorable biosafety' not detailed quantitatively. In a 4T1 breast tumor model, combined treatment markedly suppressed tumor growth with favorable biosafety under tested conditions.
This work is exploratory and does not directly inform clinical practice. It may guide future nanoparticle engineering for tumor-microenvironment-responsive therapy, but requires validation in larger animal cohorts, efficacy comparators, and eventual human translation before clinical relevance can be assessed.
Early-stage preclinical study demonstrating a novel nanoparticle design in cell culture and a single murine tumor model, without clinical translation, efficacy comparators, or mechanistic validation beyond correlative evidence.
As stated by the source record.
Quoted from the source exactly as published.
This work is exploratory and does not directly inform clinical practice. It may guide future nanoparticle engineering for tumor-microenvironment-responsive therapy, but requires validation in larger animal cohorts, efficacy comparators, and eventual human translation before clinical relevance can be assessed.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Cu–Fe Prussian blue analogues (PBAs) are promising platforms for nanocatalytic medicine owing to their redox-active Cu/Fe centers and open metal–cyano coordination frameworks. Nevertheless, the influence of Cu deficiency on their enzyme-mimetic catalytic behavior in tumor-relevant environments containing phosphate and glutathione (GSH) remains poorly defined. Here, we constructed a Cu-deficient Cu–Fe PBA core (CuPBA-D), loaded it with hematoporphyrin monomethyl ether (HMME), and coated it with hyaluronic acid (HA) to yield CuPBA-D/HMME/HA for microenvironment-responsive catalytic/sonodynamic cancer therapy. Etching-induced Cu deficiency altered the local Cu/Fe electronic environment, strengthened H 2 O 2 adsorption and activation, and enhanced catalytic activity, as supported by experimental results and density functional theory (DFT) calculations. CuPBA-D displayed pH-dependent H 2 O 2 conversion, with O 2 •− generation favored under mildly acidic conditions and O 2 evolution becoming more prominent near neutrality. Phosphate-containing media also increased the surface fractions of higher-valence Cu/Fe species and accelerated CuPBA-D-mediated GSH consumption, supporting phosphate-facilitated interfacial redox remodeling. In addition, CuPBA-D underwent GSH-concentration-dependent framework disassembly when phosphate and GSH coexisted, indicating coupled interfacial redox and structural evolution. The CAT-like O 2 -generating activity of CuPBA-D increased oxygen availability for HMME-mediated 1 O 2 production during ultrasound irradiation, thereby strengthening the sonodynamic response. In vitro, CuPBA-D/HMME/HA plus ultrasound increased intracellular ROS accumulation and induced ferroptosis-associated damage, supported by biochemical, ultrastructural, and transcriptomic analyses. In a 4T1 breast tumor model, the combined treatment markedly suppressed tumor growth while showing favorable biosafety under the tested conditions. Collectively, these findings identify phosphate/GSH-coupled redox remodeling in Cu-deficient Cu–Fe PBAs and provide a design basis for tumor-microenvironment-responsive nanoplatforms integrating catalytic ROS generation, redox disruption, and O 2 -assisted sonodynamic therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.